Sigyn Therapeutics, Inc. (SIGY) stock
SIGYOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2025, quý kết thúc ngày Sep 30, 2025Last filing: 10-Q on Nov 14, 2025Score 0/30
$0.03+0.00 (0.00%)
Close on Oct 19, 2026Market cap $48.16KP/E –Yield –
Sigyn Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Sigyn Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2025 was $140.10K, down 84.3% year over year. For fiscal 2024 it was $773.28K, down 3.1% from the year before. The highest annual figure on record is $798.17K in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $773.28K | -3.1% |
| FY2023 | Dec 31, 2023 | $798.17K | +21.4% |
| FY2022 | Dec 31, 2022 | $657.66K | -10.4% |
| FY2021 | Dec 31, 2021 | $734.01K | +75.0% |
| FY2020 | Dec 31, 2020 | $419.36K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2025 | Sep 30, 2025 | $29.68K | -85.6% |
| Q2 FY2025 | Jun 30, 2025 | $7.48K | -96.9% |
| Q1 FY2025 | Mar 31, 2025 | $8.84K | -96.2% |
| Q4 FY2024 | Dec 31, 2024 | $94.10K | -56.4% |
| Q3 FY2024 | Sep 30, 2024 | $206.16K | -4.2% |
| Q2 FY2024 | Jun 30, 2024 | $240.43K | +9.7% |
| Q1 FY2024 | Mar 31, 2024 | $232.59K | +57.3% |
| Q4 FY2023 | Dec 31, 2023 | $215.93K | +53.3% |
| Q3 FY2023 | Sep 30, 2023 | $215.23K | +60.9% |
| Q2 FY2023 | Jun 30, 2023 | $219.16K | +41.7% |
| Q1 FY2023 | Mar 31, 2023 | $147.84K | -35.3% |
| Q4 FY2022 | Dec 31, 2022 | $140.86K | -43.7% |
| Q3 FY2022 | Sep 30, 2022 | $133.77K | -41.2% |
| Q2 FY2022 | Jun 30, 2022 | $154.68K | +10.7% |
| Q1 FY2022 | Mar 31, 2022 | $228.34K | +96.0% |
| Q4 FY2021 | Dec 31, 2021 | $250.26K | -40.0% |
| Q3 FY2021 | Sep 30, 2021 | $227.50K | – |
| Q2 FY2021 | Jun 30, 2021 | $139.74K | – |
| Q1 FY2021 | Mar 31, 2021 | $116.52K | +5790.6% |
| Q4 FY2020 | Dec 31, 2020 | $417.38K | – |
| Q3 FY2020 | Sep 30, 2020 | $0 | – |
| Q2 FY2020 | Jun 30, 2020 | $0 | – |
| Q1 FY2020 | Mar 31, 2020 | $1.98K | – |
See a number that looks wrong?